CytoMed Therapeutics Ltd SEC filings GDTC
CytoMed Therapeutics Ltd has 132 filings in SEC EDGAR's recent list, going back to Sep 28, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 13, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 23, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 16, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 13, 2026 | — |
| 144 | Notice of proposed sale | Aug 11, 2026 | — |
| 4/A | Filing | Jul 24, 2026 | Jul 14, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 24, 2026 | — |
| 4 | Insider transaction | Jul 24, 2026 | Jul 14, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 8, 2026 |
| 3 | Initial insider ownership | May 26, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 144 | Notice of proposed sale | May 13, 2026 | — |
| 144 | Notice of proposed sale | Feb 12, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 29, 2025 | — |
| 144 | Notice of proposed sale | Sep 22, 2025 | — |
| 144 | Notice of proposed sale | Jun 23, 2025 | — |
| 144 | Notice of proposed sale | Mar 24, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 24, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 4, 2025 | — |
| 144 | Notice of proposed sale | Nov 4, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | May 23, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13D | Ownership over 5% (active) | May 19, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Apr 24, 2023 | — |
| SC 13D | Ownership over 5% (active) | Apr 21, 2023 | — |
| 3 | Initial insider ownership | Apr 17, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 17, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GDTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Singapore
- Headquarters
- 1 Commonwealth Lane, Singapore
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1873093
- Former names
- CytoMed Therapeutics Pte. Ltd. (until Nov 30, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.